Abstract: A method is disclosed for lowering the concentration of a serum lipid or lipoprotein component in a mammal, including the step of administering to a mammal in need of such treatment a hypolipidemic, therapeutically effective amount of at least one creatine derivative.

Abstract: A method is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an HMG CoA reductase inhibitor such as pravastatin, alone or in combination with an ACE inhibitor.

Abstract: Urea derivatives of formula (I) ##STR1## wherein the valuable groups are as defined in the specification, which possess both an ACAT inhibitory activity and an antioxidative activity. Those derivatives are useful in the prophylaxis and treatment of hypercholesterolemia and atherosclerosis.

Abstract: The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefor. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug.

Abstract: The present invention relates to treatment of conditions wherein protein Kinase C inhibition is indicated.

Abstract: The use of extracts of Tremella fuciformis (Berk) in maintaining the permeability of microvascular walls and its effect on the microcirculatory system, especially with regard to treatment of thromboplebitis, atherosclerosis and senile degradation of microvessels, is described.

Abstract: An amine polymer includes first and second substituents bound to amines of the polymer. The first substituent includes a hydrophobic moiety. The second substituent includes a quaternary amine-containing moiety. A method for binding bile salts of bile acids in a mammal includes orally administering to the mammal a therapeutically-effective amount of the amine polymer.

Abstract: A method for increasing blood serum HDL cholesterol levels in a mammal in need of increased HDL cholesterol blood serum levels, which comprises administering to said mammal, an effective amount of a compound of formula I: ##STR1## wherein R is phenyl or phenyl optionally substituted with one or more groups selected from halogen, alkyl, perfluoroalkyl, alkoxy, perfluoroalkoxy, hydroxy, alkanoyloxy, aroyloxy or arylalkanoyloxy; R.sup.3 is alkyl, aryl or arylalkyl; or a pharmaceutically acceptable salt thereof.

Abstract: TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation of vascular smooth muscle cells over time. Further provided is a method for upregulating cellular mRNA coding for TGF-beta.

Abstract: A medicament for the treatment and/or prophylaxis of restenosis and arterial sclerosis after percutaneous transluminal angioplasty, characterized in that the medicament contains batroxobin as an effective component.

Abstract: Disclosed are novel saponins containing 5-C-hydroxymethylhexose and a sterol or triterpene. These materials, when consumed by humans and animals, lower the cholesterol level in the blood. These compounds can be administered as pharmaceutical preparation to the diet, or incorporated into food compositions.

Abstract: A pharmaceutical composition suitable for the treatment of a condition selected from the group consisting of cardiovascular disease, cerebrovascular disease, Alzheimer's disease, depression or combinations thereof comprising various mixtures of the aqueous extracts of tissue of specific Chinese plants and herbs. A method of preparing the pharmaceutical compositions of the invention and a method for treating a patient therewith are also disclosed.

Abstract: Water-soluble, high-viscosity grade cellulose ether compositions are useful for the reduction of serum lipid levels, particularly total serum cholesterol, serum triglycerides, and low-density lipoprotein (LDL) levels and/or attenuate the postprandial rise of blood glucose levels in animals. The pharmaceutical uses of compositions for reducing cholesterol levels additionally include the treatment of diabetes and/or hypercholesterolemia, with avoidance of many of the undesirable side effects associated with other forms of treatment. The composition may be in the form of a prehydrated ingestible composition, such as a gelatin, or a comestible, such as a cookie. In addition, the compositions of the present invention are palatable to the patient, thereby enhancing patient compliance with the regimen.

Abstract: This invention relates to aromatic oligomeric compounds useful in the treatment of cardiovascular, bone metabolic, hypolipidaemic, neuronal, gastrointestinal and elastase-mediated connective tissue degradation disorders and disorders which may be treated by agents effective in binding DNA, to processes for preparation of such oligomeric compounds, to pharmaceutical compositions including such oligomeric compounds, and to their use in the treatment of such disorders.

Abstract: The present invention relates to the treatment and prevention of conditions wherein protein Kinase C inhibition is indicated.

Abstract: A method for increasing the HDL cholesterol concentration in the blood of a mammal in need of increased HDL cholesterol blood concentration, which comprises administering to said mammal, orally or parenterally, a compound of formula I: ##STR1## wherein R is alkyl; a substituted or unsubstituted aromatic N, O or S heterocycle; substituted or unsubstituted aryl, arylalkyl, benzhydryl or indanyl, in which the substituents are one to three members independently selected from the group consisting of alkyl, alkoxy, alkylthio, alkenyl, alkynyl, halo, perfluoroalkyl, perfluoroalkyl or hydroxy; and R.sup.1 is aryl, alkyl, alkenyl, alkynyl or substituted aryl where the substituents are one to three members independently selected from the group consisting of alkyl, alkoxy, alkylthio, alkenyl, alkynyl, halo, perfluoroalkyl, perfluoroalkoxy or hydroxy.

Abstract: A nutritional product having a solid matrix containing protein, fat and carbohydrate has disposed therein particles of dietary fiber encapsulated in zein. The preferred dietary fiber is guar. Such a nutritional product may be used for reducing the serum cholesterol in a mammal.

Abstract: This invention relates to the use of certain hydroxylated metabolites and derivatives of doxazosin and their pharmaceutically acceptable acid addition salts for retarding the development of atherosclerosis in a mammal. Such compounds are useful for reducing atherosclerotic plaque involvement and for retarding and reducing both lipid deposition fibrosis in the development of atherosclerotic plaques.

Abstract: A novel pharmaceutical use of a dihydropyridine derivative of the formula (I) ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and each is an alkyl or the like; R.sub.4 is a hydrogen atom or the like; R.sub.5 is nitro, a halogenated alkyl, cyano or the like; X is a vinylene or an azomethine; A is an alkylene; and B is --N(R.sub.6) (R.sub.7) or a group of the formula ##STR2## wherein R.sub.6 and R.sub.7 are the same or different and each is an alkyl, an aralkyl, an aryl or the like; R.sub.8 and Ar are aryl or the like; and n is 0, 1 or 2, or an acid addition salt thereof for promoting PGI.sub.2 production, and for the treatment and prevention of hyperlipemia, arteriosclerosis and cerebral diseases.

Abstract: The present invention relates to novel triaryl-ethylene derivatives that are useful as anti-neoplastic agents, antiatherosclerotic agents, and hypocholesterolemic agents.

Abstract: Proposed is a method for vascular embolization of the blood vessel of a patient by introducing an aqueous solution of a specific thermosensitive polymer, which is liquid at low temperatures but causes coagulation when heated up to the body temperature of the patient, into the blood vessel followed by in situ heating of the solution. The thermosensitive polymer found to be suitable for the purpose is a homopolymer or copolymer of an N-substituted (meth) acrylamide monomer having a specified intrinsic viscosity in tetrahydrofuran and gives an aqueous solution capable of exhibiting phase transition from a liquid to a coagulate at a transition temperature of 10.degree. to 37.degree..

Abstract: A method of preventing or treating hyperproliferative vascular disease in a mammal consists of administering to a mammal an effective amount of carboxyamide compounds.

Abstract: In a preferred embodiment, drugs having pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as the active ingredient one or more N-substituted 2-(1H) pyridone(s). The composition of this invention is novel as an anti-fibrotic drug, namely, as an agent for treating fibrosis. Any existing compounds have not been shown to be effective for the reparation and prevention of fibrotic lesions.

Abstract: Methods for treatment of humans and other animals with dimercaptosuccinic acid (DMSA). DMSA is administered to reduce levels of silicon in blood and tissue, reduce blood pressure, improve kidney function, prevent or retard the progression of chronic renal failure, treat the accumulation of silicon in advanced kidney disease, decrease accumulation of reactive oxygen metabolites, increase superoxide dismutase activity, and/or prevent the onset or improve the current status of senile dementia or Alzheimer's disease.

Abstract: Blended cholesterol-reduced animal fat and vegetable oil which are combined in a proportion such that the weight ratio of linoleic acid (18:2) content divided by myristic acid (14:2) content is between 2 and 9 inclusive.In addition, cholesterol-reduced animal fact can be blended with cholesterol-reduced fish oil to stabilize the fish oil against air-oxidation at room temperature.

Abstract: The present invention relates to an agent for the suppression or lowering of blood lipids, cholesterol and neutral fats, which is derived from a plant and comprises, as an effective ingredient, an edible dietary fiber which contains cellulose and lignin as its main constituents and maintains the cellulose and lignin in a bonded state as in the plant.

Abstract: The present invention provides a novel formulation of matter and a novel process for making it. In particular, the present invention provides unique and novel 1000 mg tablets of Colestipol hydrochloride having the advantageous properties of hardness and low friability and a novel process for making such tablets.

Abstract: Retinoids are effective to lower plasma levels of Lp (a) in mammals.

Abstract: A method for the treatment of atherosclerosis by administering to a patient in need of anti-atherosclerotic treatment, an effective amount of 17 alpha-dihydroequilin, a C.sub.2 -C.sub.6 alkanoyloxy ester thereof or a pharmaceutically acceptable salt of it's sulfate or phosphate ester, in the absence of naturally occurring estrogenic sreroids. A pharmaceutical composition containing 17 alpha-dihydroequilin, a C.sub.2 -C.sub.6 alkanoyloxy ester thereof or a pharmaceutically acceptable salt of it's sulfate or phosphate ester, in the absence of naturally occurring estrogenic sreroids, and a pharmaceutically acceptable carrier therefor.

Abstract: Compounds of the formula: ##STR1## are useful for treating conditions modulated by .alpha..sub.1 -adrenergic receptors.

Abstract: Disclosed is a tricyclic compound represented by the formula (I): ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represents hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, amino, C1-6 alkylamino, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, halogen, nitro, cyano, carboxy, C1-6 alkoxycarbonyl, hydroxymethyl, CR.sup.9 R.sup.10 CO.sub.2 R.sup.11 (wherein each of R.sup.9, R.sup.10 and R.sup.11 independently represents hydrogen or C1-6 alkyl) or CONR.sup.12 R.sup.13 (wherein each of R.sup.12 and R.sup.13 independently represents hydrogen or C1-6-alkyl); R.sup.5 represents hydrogen or C1-6 alkyl; each of R.sup.6, R.sup.7 and R.sup.8 independently represents hydrogen, C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkanoyloxy, C1-6 alkylthio, thiocyanato or halogen; X represents CH or N; Y.sup.1 -Y.sup.2 represents CH.sub.2 -O, CH.sub.2 -S(O).sub.n, (wherein n represents 0, 1, or 2), CH.sub.2 CH.sub.2, CH.dbd.CH or CON(R.sup.14) (wherein R.sup.

Abstract: This invention relates to a lipid metabolism improving medicinal composition containing a phosphoric acid diester compound of the formula or a pharmacologically acceptable salt thereof. ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and each represents a hydrogen atom or a methyl group.The lipid metabolism improving medicinal composition of this invention lowers the plasma levels of triglycerides (TG), non-esterified fatty acids (NEFA), total cholesterol (T-ch), esterified cholesterol (E-ch), free cholesterol (F-ch), total lipid (TL) and lipid peroxides (LPO) and, among cholesterol fractions, increases the high-density lipoprotein (HDL) fraction and reduces the low-density ipoprotein (VLDL) fractions. Therefore, the composition can be used with advantage for the amelioration of hyperlipidemia associated with arteriosclerotic diseases such as myocardial infarction, angina pectoris, cerebral infarction, cerebral arteriosclerosis, etc.

Abstract: TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation of vascular smooth muscle cells over time. Further provided is a method for upregulating cellular mRNA coding for TGF-beta.

Abstract: Novel sulfoximine and sulfodiimine matrix metalloproteinase inhibitors of the formula, ##STR1## wherein: R.sup.1 is selected from the group consisting of lower-alkyl, hydroxy lower-alkyl, amino lower-alkyl, carbamoyl lower-alkyl, lower-alkyl carbonyl, lower-alkyoxyalkyl, aralkyl and heteroaralkyl;X is NH or O;R.sup.2 is selected from the group consisting of hydrogen, lower-alkyl and aralkyl;R.sup.3 is selected from the group consisting of hydrogen, lower-alkyl, amino lower-alkyl, guanyl lower-alkyl, aralkyl and heteroaralkyl; andR.sup.4 is selected from the group consisting of lower alkyl, aralkyl and --CH(R.sup.5)--C(O)NH.sub.2,wherein R.sup.5 is selected from the group consisting of hydrogen, lower-alkyl, amino lower-alkyl, guanyl lower-alkyl, imidazoylalkyl, hydroxymethyl, 1-hydroxyethyl, mercapto lower-alkyl, and methylthio lower-alkyl;useful for modulating physiological functions or treating diseases and disease conditions associated with matrix metalloproteinase modulation.

Abstract: A prophylactic and remedial preparation for a disease attendant on hyperglycemia, a preparation for depressing the rise in blood sugar, and a wholesome food separately include, as an active ingredient, at least one component selected from the group consisting of L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose.

Abstract: Methods for inhibiting the attachment of platelets to a site of an injury are provided. The methods involve administering to a subject that has sustained an injury an effective amount of a platelet binding-site agent. Preferred platelet binding-site agents are platelets that are substantially free of platelet substances contained in lysosomes, dense granules or alpha granules.

Abstract: The invention concerns novel cross-linked poly(N,N-dialkylallyl)ammonium polymer materials containing quaternary propylammonium structural units which are effective in lowering elevated plasma levels of low density lipoproteins and lipoid components thereof, such as cholesterol, and which are of value in the treatment of conditions in which such elevated plasma levels are associated, for example, various vascular diseases. The invention also provides methods for the manufacture of the polymer materials and various intermediates for use in such manufacture.

Abstract: The oligomers of the present invention are polyureas or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for inhibiting the proliferation of smooth muscle cell.

Abstract: Certain dihydroxyindanone compounds, and their pharmaceutically-acceptable salts, are inhibitors of tyrosine kinase enzymes, and so are useful for the control of tyrosine kinase dependent diseases (e.g., cancer, atherosclerosis).

Abstract: Invented is a method of treatment of hyperlipidemia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective therefor amount of a substituted azaspirane.

Abstract: Cardiovascular disease is the leading cause of death in the United States. Interpreting the relative danger of a lesion within the vasculature is limited by a lack of information on the composition of lesion. It is believed that a lesion which is high in lipids is more prone to rupture followed by thrombosis than a stable highly calcific, fibrotic, high grade stenosis. To address this recent hypothesis, a method of diagnosing and treating the most problematic vascular lesions is presented. The method employs the selective uptake of a lipophilic fluorescent compound by a lesion followed by the application of excitation light to the fluorescent compound-ladened lesion causing the fluorescent compound to emit fluorescence light.

Abstract: A class of 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds is described for use in treatment of circulatory disorders such as hypertension. Compounds of particular interest are angiotensin II antagonists of the formula ##STR1## wherein A is selected from ##STR2## wherein m is one; wherein R.sup.1 is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, benzyl, cyclohexyl, cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R.sup.

Abstract: Methods and pharmaceutical compositions for reducing the biological fluid level of a lipid soluble waste in a subject are provided. The methods involve selecting a subject diagnosed as having a hyperlipidemia-associated condition and subcutaneously introducing into the subject a biodegradable implant containing a pro-inflammatory lipid that promotes formation of an angiogenic tissue capsule containing a plurality of foam cells. The pro-inflammatory lipid is delivered in an amount sufficient to attain a detectable reduction in the biological fluid level of the lipid soluble waste.

Abstract: Compounds of the formula: ##STR1## are useful for treating conditions modulated by .alpha..sub.1 -adrenergic receptors.

Abstract: The present invention provides methods for lowering serum cholesterol comprising administering to a mammal in need of treatment a serum cholesterol lowering amount of a compound of formula I or formula II ##STR1## wherein L is --CON< or --N<; andthe dotted line in the B-ring is an optional bond; or a pharmaceutically acceptable salt thereof; and ##STR2## wherein Q is a moiety having the formula ##STR3## L is --CON< or --N<; B is --O--, --S--, --CH.sub.2 -phenyl-O--, -phenyl-O--, or -benzyl-O--;G is a moiety which together with L forms a substituted or unsubstituted heterocyclic ring having at least one nitrogen atom or is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (C.sub.3 -C.sub.7)cycloalkyl, halo(lower)alkyl, cyano(lower)alkyl, carboxy(lower)alkyl, (lower)alkoxycarbonyl(lower)alkyl, (C.sub.6 -C.sub.10)aryl, (C.sub.7 -C.sub.11)aryl akyl, di(lower)alkylamino(lower)alkyl, and fluoro-substituted analogs of the foregoing;Z is --O--, --S--, --CH.sub.

Abstract: The use of galacturonic acid and derivatives thereof for preparing a medicament for the treatment of hyperlipidaemia and/or atherosclerosis is described.

Abstract: Agglomerated psyllium husk comprising edible acid uniformly dispersed throughout the agglomerating coating. Preferred are maltodextrin-containing agglomerates of psyllium husk comprising citric acid uniformly dispersed throughout the maltodextrin coating. This agglomerated psyllium husk has improved mixability and dispersibility in liquids.

Abstract: Methods of treatment of the human or animal body are provided to combat conditions responsive to lithium and/or C.sub.18-22 polyunsaturated fatty acid therapy, including conditions associated with essential lithium deficiency, and also transfer of lipid-enveloped viruses between humans or animals or between cells within a human or animal body. The methods include administration of an effective amount of a lithium salt of a C.sub.18-22 polyunsaturated fatty acid. Devices for combatting transmission of viral diseases including lithium salts of a C.sub.18-22 polyunsaturated fatty acid are also provided.

Abstract: Diaryl urea compounds having anti-atherosclerosis activity are disclosed. Preferred compounds include the compounds 1-[4-(1,2-dimethoxyethoxy)benzyl-3-(2,4-dimethoxyphenyl)-l-heptylumea and 1-heptyl-3-(2,4-dimethoxyphenyl)-l-[4-(2-methoxyethoxymethoxy)-benzyl]urea .

Abstract: A pharmaceutical composition containing as an active ingredient glimepiride. The composition is used for preventing or treating arteriosclerosis with no influence on lipid metabolism and no increase in plasma insulin level.